According to MyBio data statistics, totally 281 BD licensing deals occurred in 2021 in China pharmaceutical industry.
1. The 281 deals include 174 cross-border licenses and 107 licenses between Chinese bios.
2. The 174 cross-border licenses include 133 License-in deals and 41 License-out deals.
3. There’re totally 107 licenses between Chinese bios. Co-development has been the major collaboration model.
Below 4 characteristics have been observed for 2021 BD deals in China pharmaceutical industry. It is anticipated deals in 2022 will tend to be mature and regular.
1. Deal numbers create new high
2. The average deal value rises
3. Deals available in all dimensions in the industry
4. Innovation drives cross-regional deals
Attachment: 2021 China Pharma BD Transactions Annual Report (click for download)